Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2

Background: On March 11, 2020, the World Health Organization (WHO) officially declared coronavirus disease 2019 a global pandemic. Ivermectin and Doxycycline against SARSCoV-2 under in-vitro conditions showed beneficial results. However, large population studies with this combination are not elaborately studied, which was the aim of our study. Materials and Methods: A total of 122 patients admitted in a tertiary care centre, who tested positive for Reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 were included in the study and a total sample size of 100 patients was obtained after exclusion. 50 patients of the treatment group were treated with Ivermectin-Doxycycline combination. Results: The results had shown a significant reduction not only in mean duration of hospital (3.70 ± 2.27 days vs 4.69 ± 2.3 days), but also in complete resolution of symptoms stay (6.67 ± 2.01 days vs 4.69 ± 2.3 days). In a small subset of 10 patients RT-PCR for COVID was tested on 10 th day after the symptom onset in both the groups and there was no difference to be found. There was no significant difference in the side effect profile of either groups. Conclusion: Our study supports the benefits of utilization of combination of Doxycycline and Ivermectin in mild to moderate COVID-19 infection in terms of early recovery based on the time for symptom resolution and the mean duration of hospital stay.